Largest Venture Capital Investors in Greater D.C. – Washington Business Journal
Image: https://www.bizjournals.com
U.S.-listed shares of GlaxoSmithKline GSK, 0.12% were down 1.4% in trading on Thursday after the Food and Drug Administration said it had granted accelerated approval to the company’s endometrial cancer treatment. The immunotherapy, which was called dostarlimab and is now named Jemperli, is approved to treat patients with severe forms of this kind of cancer who have a genetic feature known as dMMR.
Amid the international effects of the COVID-19 pandemic, Maccura Biotechnology, headquartered in the city of Chengdu in China’s Sichuan Province, is still able to keep up with changing demands. The Maryland Department of Commerce first met with the well-established, global diagnostics company in 2018 with the help of the Maryland Center China.
BETHESDA, Md., April 20, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) today announced a multi-target collaboration agreement with Zentalis Pharmaceuticals (NASDAQ: ZNTL) to discover new product candidates for the treatment of cancer. Gain will use its proprietary SEE-Tx computational platform technology to identify new sites on target proteins for potential use in oncology. SEE-Tx applies a proprietary computational algorithm and supercomputer processing to the published 3D structure of proteins to discover new binding sites with the ability to modulate protein function. The intended output is newly-discovered targets or target protein interactions that can then be drugged for therapeutic benefit to intervene on protein misfolding.
RESEARCH TRIANGLE PARK — United Therapeutics has applied for a priority review voucher and submitted a new drug application to the United States Food and Drug Administration, the company announced this week. The drug, Tyvaso DPI™, is a novel dry powder inhalation formulation of treprostinil, and, if approved, will be used to treat pulmonary arterial hypertension (PAH).
The company estimates there are about 30,000 treatable patients in the United States, according to a statement.
Each quarter we bring you an update from our Johnson & Johnson Innovation – JLABS Portfolio of companies across our 13 sites, from San Diego to Shanghai. Beyond news of our companies milestones, we also report on the diversity of our JLABS Portfolio leadership as we seek to reflect the patients we serve.
Meanwhile, we look ahead this spring and beyond to the first companies moving into our JLABS @ Washington, DC site, built in collaboration with Children’s National Hospital and BARDA (Biomedical Advanced Research and Development Authority). You can always find our latest stats and companies via our JLABS Portfolio Navigator.
GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.
NEW YORK – Qiagen said on Tuesday that it has received a CE-IVD mark for its Artus SARS-CoV-2 Prep&Amp UM Kit for high-throughput PCR-based COVID-19 testing.
The kit is now commercially available in the EU and other markets accepting the CE-IVD mark, and Qiagen has submitted an Emergency Use Authorization application for the assay to the US Food and Drug Administration.
The Quantum Startup Foundry (QSF) at the University of Maryland brings together the resources needed—physical and virtual—to support entrepreneurs and startups in accelerating quantum technologies’ time to market. QSF will bring entrepreneurs together with industry and government customers, investors, technical mentors, leading-edge research and IP, and quantum-specific infrastructure (equipment, tools, facilities). Located in the Washington, DC metro area, QSF offers the perfect landing and launch spot for quantum companies.
A group of top lawmakers of both parties in both chambers of Congress on Wednesday reintroduced legislation that aims to spend $110 billion on vital technologies to sustain American leadership and spur competitiveness against China.
The draft bill, known as the Endless Frontier Act, championed by Senate Majority Leader Charles E. Schumer, D-N.Y., and Sen. Todd Young, R-Ind., is matched by a companion bill in the House by Reps. Ro Khanna, D-Calif., and Mike Gallagher, R-Wis.